Logo

American Heart Association

  2
  0


Final ID: 4138781

Neuro-specific biomarkers for risk assessment of ischemic stroke and death in patients with atrial fibrillation not receiving oral anticoagulation

Abstract Body (Do not enter title and authors here): Background: Biomarkers measured in plasma reflecting cardiorenal dysfunction and inflammation are associated with clinical outcomes in atrial fibrillation (AF). We recently showed an association between the plasma level of the neuronal biomarker neurofilament light chain (NFL) and subsequent stroke and death in patients with AF not receiving oral anticoagulation (OAC).

Purpose: We aimed to compare NFL with other circulating neuro-specific biomarkers, specifically glial fibrillary acidic protein (GFAP), tau, and ubiquitin carboxy-terminal hydrolase L1 (UCHL1), concerning associations with the risk of stroke and other outcomes in patients with AF.

Methods: Concentrations of NFL, GFAP, tau, and UCHL1 were determined with Single Molecule Array (Simoa®) in plasma samples obtained at baseline from 967 patients with AF randomized to aspirin in the ACTIVE A trial. Median follow-up was 3.6 years. Associations between baseline biomarker concentrations, clinical variables (age, sex, body mass index, smoking, alcohol consumption, type of AF, cardiac rhythm at baseline, heart failure, hypertension, diabetes, prior stroke/transient ischemic attack, peripheral arterial disease, and myocardial infarction), and outcomes (ischemic stroke, cardiovascular and all-cause death) were analysed with Cox regression, adjusting for clinical variables and other biomarkers.

Results: Increasing age and female sex were associated with elevated levels of all four biomarkers. Plasma levels of NFL were positively correlated with those of GFAP (r=0.67, p<0.001), tau (r=0.12, p<0.001), and UCHL1 (r=0.37, p<0.001). NFL was independently associated with subsequent ischemic stroke (HR 1.27, 95% CI 1.03–1.56 for a doubling of NFL), cardiovascular death (HR 1.37, 95% CI 1.13–1.64 for a doubling of NFL), and all-cause death (HR 1.46, 95% CI 1.25–1.70 for a doubling of NFL) after adjustment for clinical factors and other biomarkers. In unadjusted analyses, GFAP was associated with ischemic stroke and death; tau and UCHL1 with death only, however, these associations were not significant after adjusting for clinical variables (Table).

Conclusions: In patients with AF not receiving OAC, NFL was independently associated with ischemic stroke and death. Further investigation of NFL and its association with clinical outcomes in patients with cardiovascular disease is therefore warranted.
  • Aulin, Julia  ( Uppsala University , Uppsala , Sweden )
  • Sjolin, Karl  ( Uppsala University , Uppsala , Sweden )
  • Lindback, Johan  ( Uppsala Clinical Research Center , Uppsala , Sweden )
  • Benz, Alexander  ( McMaster University HGH , Hamilton , Ontario , Canada )
  • Eikelboom, John  ( McMaster University HGH , Hamilton , Ontario , Canada )
  • Oldgren, Jonas  ( Uppsala University , Uppsala , Sweden )
  • Wallentin, Lars  ( Uppsala University , Uppsala , Sweden )
  • Burman, Joachim  ( Uppsala University , Uppsala , Sweden )
  • Author Disclosures:
    Julia Aulin: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bissen Brainwalk Foundation:Active (exists now) ; Research Funding (PI or named investigator):Uppsala University Hospital:Active (exists now) ; Research Funding (PI or named investigator):The Swedish Heart Lung Foundation:Active (exists now) | Karl Sjolin: DO NOT have relevant financial relationships | Johan Lindback: DO NOT have relevant financial relationships | Alexander Benz: DO have relevant financial relationships ; Speaker:Bristol-Myers Squibb:Past (completed) ; Other (please indicate in the box next to the company name):Boston Scientific - participation in an educational program supported by Boston Scientific ("Fellowship Herzrhythmus"):Active (exists now) ; Speaker:AstraZeneca:Past (completed) | John Eikelboom: DO have relevant financial relationships ; Consultant:Anthos:Active (exists now) ; Speaker:USV:Active (exists now) ; Speaker:Pfizer:Active (exists now) ; Speaker:Merck:Active (exists now) ; Speaker:Janssen:Active (exists now) ; Speaker:Ionis:Active (exists now) ; Speaker:Daiichi-Sankyo:Active (exists now) ; Speaker:BMS:Active (exists now) ; Speaker:BI:Active (exists now) ; Speaker:Bayer:Active (exists now) | Jonas Oldgren: DO NOT have relevant financial relationships | Lars Wallentin: DO NOT have relevant financial relationships | Joachim Burman: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Stroke Council Award and Keynote Lecture

Monday, 11/18/2024 , 08:00AM - 09:15AM

Abstract Oral Session

More abstracts on this topic:
Alpha-1-acid glycoprotein is a potential serum Biomarker for Cerebral Amyloid Angiopathy

Nishigaki Akisato, Matsuura Keita, Ii Yuichiro, Oikawa Shinji, Tomimoto Hidekazu, Shindo Akihiro, Ishikawa Hidehiro, Nishiguchi Yamato, Tachibana Kei, Kato Natsuko, Matsuda Kana, Mori Yurie, Utsunomiya Takaya, Matsuyama Hirofumi

A Pilot Study of Post-Discharge Atrial Fibrillation Using a Novel Mobile Electrocardiography Monitoring Device

Iribarne Alexander, Kramer Robert, Moquete Ellen, Hupf Jonathan, Duncan Prezley, Mihelis Efstathia, Borger Michael, Muir Andrew, Starnes Vaughn, Edegran Albin, Fenton Kathleen, Patel Nirav, Taddei-peters Wendy, Moskowitz Alan, Ogara Patrick, Gelijns Annetine, Alexander John, Gillinov A, Bagiella Emilia, D'alessandro David, Dimaio John, Bhavnani Sanjeev, Badhwar Vinay, Sengupta Partho, Johnson Linda, Gajewska-dendek Elzbieta

More abstracts from these authors:
Restarting anticoagulation in FXa inhibitor associated intracerebral hemorrhage treated with andexanet reduces thrombotic events

Sharma Mukul, Eikelboom John, Xu Lizhen, Bamberg Krister, Falkenberg Cecilia, Ladenvall Per, Penland Robert, Narayan Rohit, Shoamanesh Ashkan

Risk of myocardial infarction in paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient-level data analysis of 71,466 patients from COMBINE AF

Ntaios Georgios, Granger Christopher, Patel Manesh, Wallentin Lars, Giugliano Robert, Goette Andreas, Palazzolo Michael, Antman Elliott, Ruff Christian, Braunwald Eugene, Link Mark, Mahaffey Kenneth, Eikelboom John

You have to be authorized to contact abstract author. Please, Login
Not Available